1 active not recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow EGFR Exon 20 Mutation: new trials by email Literature Review of EGFR Exon 20 Mutation trials Research Report on EGFR Exon 20 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer CLN-081 - Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | Phase 1 / Phase 2 | Active not recruiting | Cullinan Therapeutics Inc. | 284 | 2019-10-31 | 2026-06-17 |
| Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Poziotinib - EGFR Exon 20 Mutation, ERBB2 Gene Mutation | Phase 2 | Terminated | M.D. Anderson Cancer Center | 93 | 2017-03-17 | 2026-02-20 |
Carcinoma, Non-Small-Cell Lung (2)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
HM781-36B (1) · zipalertinib (1)
Cullinan Therapeutics Inc. (1) · M.D. Anderson Cancer Center (1)
United States (2) · Hong Kong (1) · Italy (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)
Yasir Y Elamin (1) · Zosia Piotrowska, MD (1)
PMID 33122578, PMID 34550757, PMID 35820397, PMID 37384848, PMID 40450572, PMID 40782807